0.9% Sodium Chloride (Placebo)

DRUG4 trials

Sponsors

Community Medical Center, Scranton, PA, Sanaria Inc., University of Liverpool, Charite University, Berlin, Germany

Conditions

Acute PancreatitisCardiovascular DiseaseCardiovascular Risk FactorChronic Kidney Disease Requiring Chronic DialysisHaemodialysisHyperoxalemiaKidney InjuryMalaria

Phase 1

Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis

CompletedNCT02115516

Sanaria Inc.Malaria, Plasmodium Falciparum Malaria

Start: 2014-04-30End: 2016-04-30Updated: 2017-05-15

Phase 2

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

CompletedNCT00921518

Community Medical Center, Scranton, PAKidney Injury

Start: 2009-01-31End: 2012-01-31Updated: 2014-04-15

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)

RecruitingNCT03684278

University of LiverpoolAcute Pancreatitis

Start: 2019-05-01End: 2027-03-31Target: 290Updated: 2025-09-04

Lumasiran in Hyperoxalaemic Patients on Haemodialysis

RecruitingNCT06225544

Charite University, Berlin, GermanyCardiovascular Disease, Cardiovascular Risk Factor, Chronic Kidney Disease Requiring Chronic Dialysis +2

Start: 2024-04-14End: 2025-03-01Target: 50Updated: 2024-08-21

Related Papers

Effect of controlled human Plasmodium falciparum infection on B cell subsets in individuals with different levels of malaria immunity

Medical Microbiology and Immunology2025-09-27

Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.

2015-03-18103 citations